Corient Private Wealth LLC Has $851,000 Stake in Smith & Nephew plc (NYSE:SNN)

Corient Private Wealth LLC increased its position in Smith & Nephew plc (NYSE:SNN) by 6.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 34,640 shares of the medical equipment provider’s stock after buying an additional 2,197 shares during the period. Corient Private Wealth LLC’s holdings in Smith & Nephew were worth $851,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. increased its stake in shares of Smith & Nephew by 29.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 27,199 shares of the medical equipment provider’s stock worth $847,000 after purchasing an additional 6,164 shares during the last quarter. Stifel Financial Corp bought a new stake in Smith & Nephew in the third quarter worth $1,258,000. Maverick Capital Ltd. acquired a new position in Smith & Nephew during the third quarter worth $2,086,000. Blue Trust Inc. raised its holdings in Smith & Nephew by 26.0% during the fourth quarter. Blue Trust Inc. now owns 5,871 shares of the medical equipment provider’s stock valued at $144,000 after buying an additional 1,213 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of Smith & Nephew by 31.8% in the fourth quarter. GAMMA Investing LLC now owns 2,975 shares of the medical equipment provider’s stock worth $73,000 after buying an additional 718 shares during the last quarter. Institutional investors own 25.64% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Canaccord Genuity Group reissued a “hold” rating and set a $27.00 price objective on shares of Smith & Nephew in a report on Monday, March 17th. UBS Group downgraded Smith & Nephew from a “buy” rating to a “neutral” rating in a report on Wednesday, March 12th. Finally, StockNews.com upgraded shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $27.00.

Smith & Nephew Price Performance

NYSE SNN opened at $28.42 on Friday. The stock has a 50-day simple moving average of $27.07 and a 200 day simple moving average of $27.02. Smith & Nephew plc has a twelve month low of $23.65 and a twelve month high of $31.72. The stock has a market capitalization of $12.43 billion, a PE ratio of 13.16, a P/E/G ratio of 1.26 and a beta of 0.83. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51.

Smith & Nephew Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Friday, March 28th will be given a $0.447 dividend. This represents a dividend yield of 2.5%. This is a boost from Smith & Nephew’s previous semi-annual dividend of $0.29. The ex-dividend date is Friday, March 28th. Smith & Nephew’s dividend payout ratio is currently 41.20%.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.